| Variable | beta Coefficient | SE | P value |
| --- | --- | --- | --- |
| Gender: Female | -0.29650 | 0.10584 | 0.0053 |
| Disease stage & CNS metastases: M1c/M1d no BM | -0.21340 | 0.14438 | 0.1402 |
| Disease stage & CNS metastases: III/M1a/M1b | -0.59802 | 0.16081 | 2e-04 |
| Immunosuppressive medications: yes | 0.37702 | 0.15176 | 0.0134 |
| Other malignancies: yes | 0.34696 | 0.15164 | 0.0226 |
| Performance status: 2/3/4 | 1.00535 | 0.13335 | p < 0.0001 |
| LDH level (log) | 0.52786 | 0.08777 | p < 0.0001 |
| Age | -0.00096 | 0.00846 | 0.9097 |
| Age' | 0.01495 | 0.00887 | 0.0928 |
| S0(no treatment) = 0.37374, 0.2959, 0.24997, 0.2004 (1, 2, 3, 4-year survival baseline hazard function, no treatment) S0(anti-PD-1) = 0.679, 0.47023, 0.38378, 0.28635 (1, 2, 3, 4-survival baseline hazard function, Anti-PD-1 treatment) S0(Anti-PD-1 plus Anti-CTLA-4) = 0.61427, 0.44714, 0.34122, 0.31653 (1, 2, 3, 4-survival baseline hazard function, Anti-PD-1 plus Anti-CTLA-4 treatment) S0(BRAF-inhibitors based) = 0.53886, 0.30428, 0.17171, 0.15744 (1, 2, 3, 4-survival baseline hazard function, BRAF-inhibitors based treatments) | | | |